PRL and neoplasm: These highly differentiated PitNETs are exquisitely susceptible to dopamine agonist therapies that result in tumor shrinkage and normalization of PRL levels,22 and over the past 40 years the availability of novel dopamine agonists has resulted in a significant reduction of patients requiring surgery and some ultimately resolve with medical therapy alone.